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Chronic activation of mammalian target of rapa-
mycin complex 1 (mTORC1) and p70 S6 kinase
(S6K) in response to hypernutrition contributes to
obesity-associated metabolic pathologies, including
hepatosteatosis and insulin resistance. Sestrins
are stress-inducible proteins that activate AMP-
activated protein kinase (AMPK) and suppress
mTORC1-S6K activity, but their role in mammalian
physiology and metabolism has not been investi-
gated. We show that Sestrin2—encoded by the
Sesn2 locus, whose expression is induced upon hy-
pernutrition—maintains metabolic homeostasis in
liver of obese mice. Sesn2 ablation exacerbates
obesity-induced mTORC1-S6K activation, glucose
intolerance, insulin resistance, and hepatosteatosis,
all of which are reversed by AMPK activation.
Furthermore, concomitant ablation of Sesn2 and
Sesn3 provokes hepatic mTORC1-S6K activation
and insulin resistance even in the absence of nutri-
tional overload and obesity. These results demon-
strate an important homeostatic function for the
stress-inducible Sestrin protein family in the control
of mammalian lipid and glucose metabolism.
INTRODUCTION
Overnutrition and sedentary lifestyle are major contributors to
the obesity epidemic, which affects one-third of United States
adults and up to 1 billion people worldwide (Haslam and James,Cell Me2005). As a consequence, obesity-associated diseases, such as
diabetes, cardiovascular disease, and nonalcoholic fatty liver
disease, have become a major public health problem. Obesity
also increases cancer risk, with the most pronounced effect
exerted on hepatocellular carcinoma, the prevalent type of liver
cancer (Calle et al., 2003). In obese individuals, excessive nutri-
ents are stored as fat in liver and adipose tissues. Accumulation
of fat droplets in the liver, a condition known as hepatosteatosis,
can eventually lead to chronic liver inflammation (steatohepati-
tis), liver damage, diabetes, and liver cancer (Angulo, 2002).
mTORC1 is an evolutionarily conserved protein kinase that
senses nutrient availability and controls cellular metabolism.
Nutritional abundance can lead to chronic mTORC1 activation,
thereby enhancing protein and lipid biosynthesis and inhibiting
autophagic catabolism (Um et al., 2006; Zoncu et al., 2011).
Through its substrate, S6K, mTORC1 causes inhibitory serine
phosphorylation of insulin receptor substrates (IRSs), thereby
contributing to insulin resistance and subsequent attenuation
of insulin-induced AKT activity (Bae et al., 2012; Um et al.,
2006). Chronic inhibition of autophagy attenuates clearance of
liver lipid droplets (LDs), thereby contributing to hepatosteatosis
(Singh et al., 2009). Thus, chronic mTORC1 activation upon
persistent hypernutrition and lack of exercise can give rise to
insulin resistance and lipid accumulation and eventually drive
the pathogenesis of type II diabetes and steatohepatitis (Zoncu
et al., 2011). Downregulation of autophagy can also lead to
accumulation of damaged mitochondria and reactive oxygen
species (ROS), giving rise to tissue degeneration and increased
cancer risk (Mizushima and Komatsu, 2011).
To avoid the pathogenic consequences of chronic mTORC1
activation, several negative feedback loops have evolved. Using
Drosophila as a model organism, we found that chronic dTORC1
activation results in transcriptional activation of the dSesn locus
that encodes for Drosophila Sestrin (dSestrin) (Lee et al., 2010).tabolism 16, 311–321, September 5, 2012 ª2012 Elsevier Inc. 311
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proteins, which in mammals includes Sestrin1, Sestrin2, and
Sestrin3 (Budanov et al., 2010). Once induced, the Sestrins
potentiate AMPK activation and thereby enhance phosphory-
lation of tuberous sclerosis complex 2 (TSC2), which in turn
attenuates mTORC1 activation and stimulates autophagy
(Budanov and Karin, 2008; Maiuri et al., 2009). The AMPK-acti-
vating and mTORC1-suppressing activities of the Sestrins are
conserved between insects and mammals (Lee et al., 2010),
but the physiological functions of the mammalian Sestrins
remain to be identified. Loss of dSestrin results in diverse age-
and obesity-associated pathologies, such as fat accumulation
and cardiac dysfunction, all of which are precipitated by acti-
vation of dTORC1 (Lee et al., 2010). Given the biochemical
similarities between Drosophila and mammalian Sestrins, we
postulated that mammalian Sestrins may also have important
homeostatic functions during conditions that cause excessive
mTORC1 activation. Here we describe such a function for
Sestrin2 and Sestrin3 in control of liver insulin resistance and
lipid accumulation before and during obesity.
RESULTS
Sestrin2 Deficiency Enhances Obesity-Induced Insulin
Resistance and Diabetic Progression
Sesn2/ mice are fully viable and do not display any gross
developmental abnormalities (Budanov and Karin, 2008). Body
weight as well as glucose homeostasis and insulin responsive-
ness evaluated by glucose tolerance (GTT) and insulin tolerance
(ITT) tests, respectively, were not significantly different between
control (Con; either Sesn2+/+ or Sesn2+/) and Sesn2/ mice
when maintained on normal chow (low-fat diet [LFD]) (Figures
S1A–S1C available online).
Expression of Sesn2 mRNA in liver was elevated in mice kept
on high-fat diet (HFD), in which 60% of the calories were fat
derived, while Sesn1 and Sesn3 messenger RNAs (mRNAs)
were not affected (Figure S1D). As a result, Sestrin2 protein
accumulated in liver of obese mice kept on HFD (Figures S1E–
S1G). Loss of Sestrin2 had marginal effects on liver Sestrin1
and Sestrin3 expression in obese mice (Figures S1G–S1I).
Obesity-induced accumulation of Sestrin2 was also observed
in skeletal muscle, but not in adipose tissue (Figure S1G). Since
Sestrin2 is an obesity-inducible protein, we examined whether
Sestrin2 deficiency affected weight gain and glucose homeo-
stasis in mice kept on HFD. As observed in LFD animals,
Sesn2/ mice on HFD did not differ in weight gain (Figure S1J)
or food consumption (Figure S1K) from Con mice. Nonetheless,
the Sestrin2 deficiency had a pronounced effect on glucose
homeostasis and insulin responsiveness in mice kept on HFD.
GTT and ITT indicated a significantly higher degree of glucose
intolerance (Figures 1A and 1B) and insulin resistance (Figures
1C and 1D) in Sesn2/ mice relative to their Con counterparts
after 3 months of HFD. However, there was no significant defect
in insulin secretion during GTT (Figure S1L).
To examine the effect of Sestrin2 ablation in a geneticmodel of
obesity, we intercrossed Sesn2/ and Lepob/ob mice. As seen
with diet-induced obesity, Lepob/ob/Sesn2/ mice were more
glucose intolerant (Figures 1E and 1F) and insulin resistant
(Figures 1G and 1H) than Lepob/ob/Sesn2+/ mice. However,312 Cell Metabolism 16, 311–321, September 5, 2012 ª2012 Elseviethe Sestrin2 deficiency had no effect on body weight (Fig-
ure S1M) or food consumption (Figure S1N) of Lepob/ob mice.
Magnetic resonance imaging (MRI) of Lepob/ob/Sesn2+/ and
Lepob/ob/Sesn2/ mice reaffirmed their similar body mass
and visceral and subcutaneous fat pad volumes (Figures S1O
and S1P). Nonetheless, at 4 months of age, Lepob/ob/Sesn2/
mice became severely diabetic, exhibiting much higher fasting
blood glucose than Lepob/ob/Sesn2+/ mice (Figure 1I), and
started excreting large amounts of glucose in their urine
(Figure 1J).
Sesn2–/–Mice Display Defective Insulin Responsiveness
in Liver and Adipose Tissue
To better understand the basis for defective glucose homeo-
stasis and insulin responsiveness in obese Sesn2/ mice, we
performed hyperinsulinemic-euglycemic clamp studies (Figures
S2A–S2C). Upon insulin infusion, Sesn2/ mice kept on HFD
exhibited a significantly lower glucose infusion rate (GIR), con-
firming thepresenceofwhole-body insulin resistance (Figure 2A).
However, Sesn2/ mice did not differ from Con mice with
respect to insulin-stimulated glucose disposal rate (IS-GDR),
indicative of muscle insulin responsiveness (Figure 2B).
However, suppression of hepatic glucose production (HGP)
during the hyperinsulinemic-euglycemic clampwas substantially
reduced in Sesn2/ mice (Figure 2C). Consequently, more than
80% of the effect of Sestrin2 loss on GIR reduction was attribut-
able to the decreased HGP suppression, while the contribution
of insulin-induced glucose uptake changes in peripheral tissues
was minimal and not statistically significant. These indications
suggest that defective glucose homeostasis in Sesn2/ mice
is largely due to decreased hepatic insulin sensitivity.
We also examined insulin responsiveness in adipose tissue.
Suppression of serum free fatty acids (FFAs) during the hyperin-
sulinemic-euglycemic clamp studies provides an indirect
assessment of adipocyte insulin sensitivity. Although FFA
suppression was modestly reduced in Sesn2/ mice, the
difference did not reach significance (Figures S2D and S2E).
Tomore directly measure adipose tissue insulin responsiveness,
we measured insulin-induced glucose uptake by primary adipo-
cytes isolated from Con and Sesn2/ mice kept on HFD.
Whereas glucose uptake in Con adipocytes was stimulated
2.5-fold by insulin, Sesn2/ adipocytes exhibited markedly
reduced insulin responsiveness (Figures S2F and S2G), sug-
gesting that Sestrin2 controls insulin sensitivity also in adipose
tissue.
Compromised Insulin-Stimulated PI3K-AKT Signaling
in Liver of Sesn2–/– Mice
AKT is an important effector of insulin signaling in liver and
adipose tissue, mainly controlling glucose and lipid metabolism
(Manning and Cantley, 2007). To examine whether Sestrins,
which control AMPK and mTORC1 activity (Budanov and Karin,
2008; Lee et al., 2010), also modulate insulin-induced AKT
activation, we examined AKT phosphorylation in livers of Con
and Sesn2/ mice kept on HFD before and after insulin
administration. In Con liver, insulin treatment induced AKT phos-
phorylation at Thr308 and Ser473, the two sites responsible for
AKT activation. However in Sesn2/ livers, insulin-induced
AKT phosphorylation at both sites was substantially reducedr Inc.
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Figure 1. Sestrin2 Deficiency Enhances Obesity-Induced Insulin Resistance
(A–D) HFD-induced glucose intolerance and insulin resistance inWT and Sesn2/mice. After 6 hr of fasting, Con (Sesn2+/+ or Sesn2+/) and Sesn2/mice kept
on HFD for 3 months were subjected to glucose tolerance test (A, GTT, nR 16) and area-under-curve analysis (B), or to insulin tolerance test (C, ITT, nR 28) and
area-under-curve analysis (D).
(E–H) Glucose intolerance and insulin resistance caused by leptin deficiency are aggravated by Sestrin2 deficiency. After 12 hr (E and F) or 6 hr (G andH) of fasting,
4-month-old Lepob/ob/Sesn2+/ (Con) and Lepob/ob/Sesn2/ (Sesn2) mice were subjected to GTT (E, nR 4) or to ITT (G, nR 5) and area-under-curve analyses
(F and H).
(I and J) Blood (I) and urine (J) glucose measurements from Lepob/ob/Sesn2+/ (Con) and Lepob/ob/Sesn2/ (Sesn2) mice (nR 4) fed ad libitum on LFD (J) or after
the indicated fasting periods (I).
Asterisks (*) denote that the data contain measurements exceeding the detection limit of the glucose meter (600 mg/dl). Thus, the asterisk-marked data may be
higher than the plotted values. Data are presented as means ± standard error. p values were calculated using Student’s t test. See also Figure S1.
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phosphorylation of forkhead box O (FoxO) family transcription
factors, including FoxO1, leading to reduced expression of
genes that encode gluconeogenic enzymes such as phospho-
enolpyruvate carboxykinase (PEPCK). In Sesn2/ mice, AKT-
dependent FoxO1 phosphorylation was decreased (Figure 2D),
and Pepck mRNA amounts were elevated relative to Con
mice (Figure S2H). These results indicate that Sestrin2 is
required for maintenance of insulin-induced AKT activation and
its sequelae during obesity.
Consistent with the hyperinsulinemic-euglycemic clamp
studies showing that muscle insulin responsiveness is not
affected by loss of Sestrin2 (Figure 2B), insulin-induced
AKT phosphorylation was largely similar between Con and
Sesn2/ muscle tissue (Figures S2I and S2J). In Sesn2/
adipose tissue, insulin-induced AKT phosphorylation was
slightly reduced relative to Con (Figures S2K and S2L).
To find out the mechanism through which insulin-induced AKT
signaling is downregulated in Sesn2/mouse liver, we analyzedCell Meactivities of signaling components that act upstream of AKT. We
found that insulin-stimulated phosphoinositide 3-kinase (PI3K)
activity in liver of Sesn2/ mice was lower than that of Con
liver (Figures 2F and 2G). Insulin-induced tyrosine phosphoryla-
tion of IRS-1 was also reduced in Sesn2/ liver compared to
Con liver (Figure 2H), suggesting that insulin resistance in
Sesn2/ liver occurs upstream or at the level of IRS-1. Interest-
ingly, Ser632 phosphorylation of IRS-1 (corresponding to
Ser636 in human IRS-1), which opposes IRS-1 tyrosine phos-
phorylation (Boura-Halfon and Zick, 2009), was significantly
higher in Sesn2/ liver both before and especially after insulin
treatment (Figures 2H and 2I).
Sestrin2 Attenuates Chronic mTORC1 Activation
during Obesity
As Ser632 phosphorylation of IRS-1 is mediated through
S6K (Um et al., 2004), an mTORC1 target, we postulated that
Sestrin2 regulates insulin signaling sensitivity through the
AMPK-mTORC1-S6K axis. Therefore, we examined whethertabolism 16, 311–321, September 5, 2012 ª2012 Elsevier Inc. 313
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Figure 2. Sesn2–/– Mice Kept on HFD Exhibit Hepatic Insulin Resistance
(A–C) Glucose infusion rates (A, GIR), insulin-stimulated glucose disposal rates (B, IS-GDR), and suppression of hepatic glucose production (C, HGP) in Con and
Sesn2/ mice kept on HFD for 4 months during hyperinsulinemic-euglycemic clamp (nR 8).
(D–I) Livers were collected from Con (Sesn2+/+ or Sesn2+/) and Sesn2/mice kept on HFD for 4 months, after 6 hr of fasting, before (–) or 10 min after (+) insulin
injection (0.8U/kg body weight).
(D and E) Phosphorylation of AKT at Thr308 and Ser473, and FoxO1 at Ser256, was analyzed by immunoblotting (D). Ratios of phosphorylated to total AKT (nR 8)
or FoxO1 (n = 5) were quantified by densitometry, and are presented as bar graphs (E).
(F and G) Activity of PI3K was measured, and lipid phosphorylation was visualized by thin layer chromatography-autoradiography (PI3P, F) and quantified by
densitometry (G, n = 3).
(H and I) Phosphorylation of IRS-1 at Tyr1229 and Ser632 was analyzed by immunoblotting (H) and the ratio of phosphorylated to total IRS-1 is presented as a bar
graph (I, n = 5).
Data are presented as means ± standard error. p values were calculated with a Student’s t test. See also Figure S2.
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Sestrin2 and Liver Metabolic HomeostasismTORC1-S6K signaling is affected by Sestrin2 loss. As previ-
ously reported (Um et al., 2004), mTORC1-dependent activatory
S6K phosphorylation at both Thr389 and Ser411 (Ali and
Sabatini, 2005) was modestly elevated in livers of Con mice
kept on HFD compared to LFD-kept mice (Figures 3A and 3B).
However, in liver of Sesn2/ mice kept on HFD, the increase
in S6K phosphorylation compared to LFD-fed Sesn2/ and
even HFD-kept Con liver was much larger (Figures 3A and 3B),
suggesting that Sestrin2 attenuates chronic liver mTORC1-S6K
signaling upon nutritional overload. The chronic upregulation
of S6K was found in both basal and insulin-stimulated liver
tissues of Sesn2/ mice kept on HFD (Figure 3C). However,
there were no significant changes in S6K phosphorylation
between livers of Con and Sesn2/ mice kept on LFD (Figures
3A and 3B), and this is consistent with the low expression of
Sestrin2 in lean mice (Figures S1D–S1G) and the absence of
metabolic abnormalities in Sesn2/ mice kept on LFD (Figures
S1A–S1C).
We previously showed that Sestrins negatively regulate the
mTORC1-S6K axis by potentiating AMPK activation (Budanov314 Cell Metabolism 16, 311–321, September 5, 2012 ª2012 Elsevieand Karin, 2008; Lee et al., 2010). Livers of Sesn2/ mice kept
on HFD exhibited lower activatory AMPK phosphorylation
(Figures 3C and 3D) and decreased AMPK catalytic activity
(Figures 3E and S3A). Livers of Sesn2//Lepob/ob mice also ex-
hibited lower AMPK activity than Sesn2+//Lepob/ob livers
(Figures 3F and S3B). The decrease in AMPK activity was partic-
ularly striking because total AMPK amounts increased upon
Sestrin2 loss in both HFD- and Lepob-induced obese mice
(Figures 3C, S3A, and S3B), suggesting that low AMPK and
high mTORC1 activity in obese Sestrin2-deficient livers led to
a compensatory increase in AMPK protein expression. AMPK-
dependent phosphorylation of acetyl-CoA carboxylase (ACC)
at Ser79wasmodestly reduced in Sestrin2-deficient obese livers
(Figure S3C). Conversely, autophosphorylation of mTOR at
Ser2481, an indicator of mTORC1 catalytic activity (Soliman
et al., 2010), was higher in Sesn2//Lepob/ob livers than in
Sesn2+//Lepob/ob livers (Figure S3D). Correspondingly, S6K
catalytic activity, which is directly stimulated by mTORC1,
was elevated in Sesn2//Lepob/ob livers relative to Sesn2+//
Lepob/ob livers (Figures 3G and S3E). S6K-mediated inhibitoryr Inc.
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Figure 3. Sestrin2 Regulates AMPK-
mTORC1 Signaling in Liver
(A and B) Livers from 6-month-old mice of the
indicated genotypes kept on LFD or HFD for
4 months were analyzed by immunoblotting for
mTORC1-dependent S6K phosphorylation at
Thr389 and Ser411 (A). Ratio of phosphorylated to
total S6K was quantified by densitometry and
presented as bar graphs (B, nR 3).
(C and D) Livers were collected from Sesn2+/ and
Sesn2/ mice kept on HFD, after 6 hr of fasting,
before (–) or 10 min after (+) insulin injection (0.8 U/
kg body weight), and analyzed for protein phos-
phorylation and expression with indicated anti-
bodies (C). Ratio of phosphorylated to total AMPK
was presented as a bar graph (D, n = 3).
(E–G) AMPK (E and F) and S6K (G) activities in
livers of HFD-fed Con and Sesn2/ mice (E) or
Lepob/ob/Sesn2+/ and Lepob/ob/Sesn2/ mice (F
and G) were measured by kinase assays (n = 3).
Levels of immunoprecipitated kinases and
corresponding kinase activities are presented in
Figure S3.
Data are presented as means ± standard error.
p values were calculated with a Student’s t test or
two-way ANOVA. See also Figure S3.
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was also substantially elevated in Sesn2/ obese livers (Figures
S3F–S3I). Thus, Sestrin2 is a positive regulator of AMPK activa-
tion in the obese liver that is required for keeping mTORC1
activity suppressed.
Sestrin2 loss modestly decreased liver AMPK activity in lean
mice (Figure S3J). However, mTORC1 activity, monitored by its
target S6K, was similar between Con and Sesn2/ mice (Fig-
ure S3K), and insulin-induced AKT activation in liver (Figure S3L)
and in adipose tissue (Figure S3M) was also comparable
between lean Con and Sesn2/ mice. These results suggest
that, in the absence of nutritional overload or obesity, conditions
that increase Sestrin2 expression, lower AMPK activity caused
by loss of basal Sestrin2 expression is insufficient to cause
mTORC1 hyperactivation and insulin resistance.
AMPK Activation Restored Insulin Sensitivity
in Sesn2–/– Mice
If Sestrin2’s protective effect against obesity-induced insulin
resistance is exerted throughmodulation of AMPK andmTORC1
activities, restoration of AMPK activity or suppression of chronic
mTORC1 should restore insulin signaling to obese Sesn2/
mice. Therefore, we attempted to suppress chronic mTORC1
activity in Sesn2/ mice using rapamycin. Although rapamycin
administration suppressed mTORC1-S6K signaling in Sesn2/
liver, it failed to restore blood glucose homeostasis in obese
Sesn2/mice (data not shown). However, it was recently shown
that long-term rapamycin administration to mice can suppress
mTORC2, which is critical for AKT activation and insulin respon-
siveness (Lamming et al., 2012). Therefore, we used AICA-
ribonucleotide (AICAR), which can effectively suppress hepatic
mTORC1 activity through AMPK activation without affectingCell MemTORC2 (Reiter et al., 2005). Although AICAR administration
caused only a slight reduction in basal hyperglycemia and
glucose intolerance (Figures S4A and S4B), it significantly
restored insulin responsiveness of HFD-kept Sesn2/ mice
(Figure 4A), suggesting that AICAR-mediated AMPK reactivation
can correct the insulin resistance phenotype caused by Sestrin2
loss. Indeed in the liver, AICAR also restored AMPK activity and
suppressed mTORC1-S6K activity (Figure 4B), and restored
insulin-induced AKT activation (Figures 4C and S4C). Further-
more, liver-specific transduction of adenoviruses expressing
constitutively active AMPK (Ad-AMPKCA) (Figure S4D) was
sufficient to suppress insulin resistance in HFD-kept Sesn2/
mice (Figures 4D and 4E). These data strongly suggest that
Sestrin2 maintains hepatic insulin sensitivity by promoting
AMPK activation in liver.
Sestrin2 Loss Aggravates Hepatosteatosis Caused
by Dietary or Genetic Obesity
Decreased AMPK and increased mTORC1 activities are associ-
ated with fat accumulation (Kahn et al., 2005; Laplante and
Sabatini, 2009), and Sestrin is important for prevention of fat
droplet accumulation in the Drosophila fat body (Lee et al.,
2010), an equivalent of the mammalian liver (Søndergaard,
1993). Indeed, Sestrin2 deficiency aggravated hepatosteatosis
caused by dietary or genetic obesity. In lean mice, liver triglycer-
ides were only slightly elevated in Sesn2/ livers compared to
Con livers (Figure 5A). However, when mice were kept on HFD,
liver triglycerides were substantially higher in Sesn2/ livers
than in Con livers (Figure 5A). Sesn2/ livers also exhibited
increased LD accumulation revealed by oil red O staining (Fig-
ure 5B). Transmission electron microscopy (EM) showed that
the size of LDs was increased upon loss of Sestrin2 under HFDtabolism 16, 311–321, September 5, 2012 ª2012 Elsevier Inc. 315
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Figure 4. Reactivation of Hepatic AMPK Restores Insulin Resistance of HFD-fed Sesn2–/– Mice
(A) Sesn2/mice kept on HFD for 3months were subjected to daily i.p. injection of 250mg/kg body weight AICAR or vehicle (PBS) for 5 days. After 6 hr of fasting,
the mice were subjected to ITT (n = 6).
(B and C) After 10 days of AICAR or vehicle (PBS) injection, livers from the mice described above were collected after 6 hr of fasting, before (B and ‘‘–’’ in C) or
10 min after (‘‘+’’ in C) insulin injection (0.8 U/kg body weight). The livers were analyzed for protein phosphorylation and expression with the indicated antibodies.
(D) Sesn2/ mice kept on HFD for 3 months were infected with adenoviruses expressing GFP (Ad-GFP) or constitutively active AMPK (Ad-AMPKCA). After 6 hr
of fasting, ITT (n = 6) was performed at 24 hr after infection.
(E) Area-under-curve analysis of ITT data. Values from untreated Sesn2+/+ (WT) and Sesn2/ (–) mice of the same HFD cohorts were provided as reference
(nR 6).
Data are presented as means ± standard error. p values were calculated with a Student’s t test. See also Figure S4.
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mice also contained higher amounts of triglycerides than
Sesn2+//Lepob/ob livers (Figure 5A).
Diminished autophagy, as a result from Sestrin2 loss, AMPK
inhibition, and mTORC1 activation (Chan, 2009; Egan et al.,
2011; Maiuri et al., 2009), can contribute to accumulation of
LDs in liver (Singh et al., 2009). EM analysis revealed that in
livers of Con mice on HFD, many LDs were associated with vesi-
cles surrounded by double membranes (Figures 5C and S5A).
Such structures were barely detectable on the much larger
LDs in Sesn2/ hepatocytes of mice on HFD (Figures 5C,
S5B, and S5C). Based on previous reports, these structures
most likely represent autophagic vesicles (AVs) engaged in LD
digestion (Singh et al., 2009). Consistent with this, immunofluo-
rescence imaging of LDs and the AV marker LC3 showed
a considerable colocalization of both structures in Con liver but
not in Sesn2/ liver from mice kept on HFD (Figure S5D).
Although the association of LD with AV was dramatically
decreased in livers of Sesn2/ HFD-kept mice, the difference
between LFD-kept Con and Sesn2/mice was much less
prominent (Figure S5C).
Lower AMPK activity in liver could also result in decreased
mitochondrial biogenesis and reduced b-oxidation of fatty
acids, which contributes to lipid accumulation (Kahn et al.,
2005). Indeed, fewer mitochondria were observed in liver EM
images of HFD-kept Sesn2/ mice than Con mice (Figure 5E),316 Cell Metabolism 16, 311–321, September 5, 2012 ª2012 Elsevieand reduced mitochondrial content was confirmed by quan-
titative PCR of mitochondrial DNA (Figures S5E and S5F).
In addition, Sestrin2 deficiency resulted in reduced expres-
sion of two mitochondrial biogenesis marker genes, Tfam and
Nrf1 (Figures 5F and S5G). Consistent with these results,
b-oxidation of palmitic acid by liver homogenates was also
reduced upon Sestrin2 deficiency in Lepob/ob mice (Figure 5G),
and hepatic AMPK restoration through AICAR or Ad-AMPKCA
suppressed liver triglyceride accumulation (Figures S4E
and S4F).
Chronic AMPK downregulation and mTORC1 activation can
promote processing and nuclear translocation of the lipogenic
transcription factor SREBP (Li et al., 2011; Porstmann et al.,
2008). Correspondingly, Sesn2//Lepob/ob livers contained
more processed SREBP than Sesn2+//Lepob/ob livers, and the
processed SREBP was translocated into the nucleus (Figures
S5H–S5J). However, Sestrin2 loss caused only a modest
increase in SREBP-dependent gene expression and the effects
varied between mice with dietary and genetic obesity (Figures
S5K and S5L). The lipogenic activity of the Sesn2//Lepob/ob
liver was also not significantly increased when compared to
control Sesn2+//Lepob/ob livers (Figure S5M). These results
suggest that the decreased lipid b-oxidation in Sestrin2-deficient
livers due to reduced autophagy and/or mitochondrial biogen-
esis, rather than increased lipogenesis, is the main cause of
hepatosteatosis.r Inc.
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Figure 5. Sestrin2 Attenuates Hepatosteatosis during Obesity
(A) Elevated triglycerides in obese Sesn2/ livers. Liver triglycerides in livers of Con (Sesn2+/+ and Sesn2+/) and Sesn2/mice kept on LFD or HFD, or Lepob/ob/
Sesn2+/ or Lepob/ob/Sesn2/ mice (nR 4).
(B–D) Increased LD size in obese Sesn2/ livers.
(B and C) Liver LDs were visualized with oil red O staining (B) and EM (C) in Con and Sesn2/ mice kept on LFD or HFD. Putative autophagosomes associated
with LDs in Con livers are indicated with arrows. Scale bars represent 20 mm (white) and 5 mm (black).
(D) Quantification of maximum LD diameters from EM images (21.4 3 31.9 mm, nR 8).
(E) Quantification of mitochondria number per field from EM images.
(F) Relative Tfam and Nrf1 mRNA amounts in livers of indicated mice (nR 7).
(G) b-oxidation of C14-labeled palmitic acid (PA) was measured in liver homogenates of Lepob/ob/Sesn2+/ (Con) and Lepob/ob/Sesn2/ (Sesn2) mice (nR 5).
Data are presented as means ± standard error. p values were calculated with a Student’s t test. See also Figure S5.
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Sestrin2 and Liver Metabolic HomeostasisConcomitant Loss of Sestrin2 and Sestrin3 Causes
Spontaneous Insulin Resistance
Unlike dSesn-null flies that show spontaneous metabolic abnor-
malities (Lee et al., 2010), lean Sesn2/ mice do not develop
spontaneous hepatosteatosis or glucose homeostasis defects.
This may be due to the existence of multiple mammalian Sesn
homologs that compensate for Sestrin2 loss. To examine this
possibility, we generated Sesn3/ mice from a Sesn3-targeted
embryonic stem cell (ESC) line (Friedel et al., 2007). Sesn3/
mice were intercrossed with Sesn2/ mice to generate
Sesn2//Sesn3/ (DKO) mice (Figure S6A). Although the
DKO mice did not exhibit spontaneous obesity (Figure S6B) or
hepatosteatosis (Figure S6C) on LFD, they exhibited higher
S6K phosphorylation (Figures 6A, 6B, and S6D–S6G) and lower
insulin-induced AKT phosphorylation than Conmice (Figures 6C,
6D, and S6H–S6K) in both liver andmuscle, effects that were not
observed in LFD-fed Sesn2/mice (Figures 3A and S3L). Corre-
spondingly, DKO mice on LFD exhibited insulin resistance and
glucose intolerance (Figures 6E, 6F, and S6L), relative to Con
mice. These results suggest that both Sestrin2 and Sestrin3
are required for proper blood glucose homeostasis under normal
conditions.
Sestrins Promote AKT Phosphorylation through
Inhibition of mTORC1
Finally, using cultured cells, we determinedwhether Sestrins can
regulate insulin-PI3K-AKT signaling in a cell autonomous
manner. In Sesn2/ mouse embryonic fibroblasts (MEFs),Cell Meboth basal (Figure 7A) and insulin-stimulated (Figure 7B) AKT
phosphorylation at Thr308 and Ser473 was reduced relative to
Sesn2+/ MEFs. When overexpressed in MCF7, H1299, and
HepG2 cells, Sestrin2 increased AKT phosphorylation even
without insulin stimulation (Figures 7C, S7A, and S7B). The
same effect was exhibited by Sestrin1, Sestrin3, and dSestrin
(Figures S7A and S7C), indicating that the AKT regulatory func-
tion is conserved throughout the Sestrin family. Phosphorylation
of AKT downstream targets including FoxO3A, GSK3, and TSC2,
as well as the lipid kinase activity of PI3K, was also increased
upon Sestrin2 expression (Figures S7A, S7D, and S7E). Although
mTORC1-dependent S6K phosphorylation was decreased by
Sestrin2 as previously reported (Budanov and Karin, 2008),
phosphorylation of ERK and RSK was unaffected (Figure S7D),
indicating the specificity of the Sestrin2 effect on the PI3K-AKT
signaling pathway.
Given that Sestrin2 can function as a redox regulator (Budanov
et al., 2004), it may potentiate insulin-induced AKT activation by
preventing ROS accumulation (Cao et al., 2009). However,
a redox-deficient Sestrin2 mutant (Sestrin2CS) was fully capable
of inducing AKT phosphorylation when overexpressed (Fig-
ure S7F). Expression of peroxiredoxin 1 (Prx1), which inhibits
ROS accumulation through the same pathway as Sestrin2 (Bu-
danov et al., 2004), had no effect on AKT phosphorylation (Fig-
ure S7F). These results indicate that Sestrin2 redox activity is
dispensable for the effects on AKT activation.
We examined whether AMPK activation and suppression of
mTORC1 activity are responsible for Sestrin2-induced activationtabolism 16, 311–321, September 5, 2012 ª2012 Elsevier Inc. 317
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Figure 6. Ablation of Sestrin2 and Sestrin3 Causes mTORC1 Upre-
gulation and Spontaneous Insulin Resistance
(A and B) Sesn2//Sesn3/DKOmice exhibit elevatedmTORC1-dependent
S6K phosphorylation. Livers and skeletal muscles from three 4-month-old Con
(Sesn2+/) and DKO mice kept on LFD were analyzed by immunoblotting for
S6K phosphorylation on Thr389.
(C and D) Livers and skeletal muscles were collected from Con and DKOmice,
after 6 hr of fasting, before (–) or 10 min after (+) insulin injection (0.8 U/kg body
weight), homogenized and analyzed by immunoblotting with the indicated
antibodies.
(E and F) After 6 hr of fasting, 4-month-old Con and DKO mice kept on LFD
were subjected to ITT (E, n = 3) and area-under-curve analysis (F). Data
are presented as means ± standard error. p value was calculated with
a Student’s t test.
See also Figure S6.
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Sestrin2 and Liver Metabolic Homeostasisof AKT. Indeed, activation of AKT by Sestrin2 was not observed
in Tsc2/ (Figure 7D) and Ampknull (Ampka1//Ampka2/;
Figure 7E) MEFs, in both of which mTORC1 activity is no longer
affected by Sestrins (Budanov and Karin, 2008). Silencing of
TSC2 (Figure S7G) or AMPKa1 (Figure S7H) with short hairpin
RNA (shRNA) lentiviruses also compromised activation of AKT
by Sestrin2 in the MCF7 tet-OFF cells. On the other hand, inhibi-
tion of mTORC1 through short-term treatment of rapamycin
enhanced AKT phosphorylation to the same extent as Sestrin2
expression (Figure S7I), while Sestrin2 was unable to promote
AKT activation in the absence of Rictor, a critical component
of mTORC2 (Figures S7J and S7K). These results indicate that
Sestrin2 controls AKT phosphorylation through the AMPK-
mTORC1/2 signaling axis in multiple cell types.
As observed in mammalian cells, both wild-type and redox-
inactive dSestrin induced AKT phosphorylation when expressed
in the dorsal part of Drosophila wing discs (Figures 7F–7H). Acti-
vation of AKT by Sestrin in Drosophila was mediated through
the AMPK-dTORC1 axis, since silencing of AMPK (Figure 7I) or
expression of Rheb (Figure 7J) or S6KCA (Figure 7K) suppressed
induction of AKT phosphorylation by dSestrin. In addition,
dSesn/ adult flies showed elevated blood trehalose concen-
tration (Figure S7L), suggesting that Sestrin-dependent control318 Cell Metabolism 16, 311–321, September 5, 2012 ª2012 Elsevieof AKT signaling and blood sugar homeostasis is evolutionarily
conserved.
DISCUSSION
The AMPK-mTORC1 axis is a well-established and conserved
central regulator of cellular metabolism (Kahn et al., 2005; Zoncu
et al., 2011). In cultured mammalian cells subjected to genotoxic
stress and in Drosophila, the AMPK-mTORC1 axis output is
modulated by expression of Sestrin proteins (Budanov and
Karin, 2008; Chen et al., 2010; Lee et al., 2010). However, given
the existence of three mammalian Sesn genes, whose protein
products exhibit conserved biochemical functions (Budanov
et al., 2004; Budanov and Karin, 2008), a physiological role for
Sestrins in metabolic regulation could previously be observed
only in Drosophila (Lee et al., 2010). Early experiments sug-
gested that the Sestrins regulate information flow through the
AMPK-mTORC1 axis during genotoxic or oxidative stress, which
result in their transcriptional upregulation via p53 (Budanov and
Karin, 2008) and FoxO3A (Nogueira et al., 2008). The current
results, however, indicate that the mammalian Sestrins also
have important physiological functions that are not limited to
acute stress conditions. Here we show that Sestrin2 and
Sestrin3 have physiologically relevant homeostatic functions
both before and during obesity in the control of insulin signaling
and blood glucosemetabolism. This function is probably exerted
through Sestrins’ ability to promote AMPK activation and
suppress mTORC1-S6K signaling (Budanov and Karin, 2008).
The glucose homeostasis disorder observed in obese
Sesn2/ mice is mainly due to hepatic insulin resistance, which
is reversible by AMPK reactivation through AICAR and adeno-
virus-mediated transduction. AMPK reactivation also strongly
suppressed chronic mTORC1-S6K activation and hepatosteato-
sis in livers of obese Sesn2/ mice while it promoted insulin-
induced AKT activation. Therefore, chronic downregulation of
AMPK activity upon Sestrin2 deficiency results in enhanced
mTORC1 activation, thereby attenuating insulin-induced AKT
activity. This effect is presumably due to the phosphorylation
of IRS proteins at their negative regulatory sites by the mTORC1
target S6K (Um et al., 2004). Consistent with this model, hepato-
cyte-specific ablation of TSC1, which causes mTORC1-S6K
hyperactivation, strongly inhibited insulin-induced AKT phos-
phorylation and caused glucose homeostasis defects (Yecies
et al., 2011). However, hepatocyte-specific ablation of AMPK
did not cause spontaneous insulin resistance on its own (Foretz
et al., 2010), raising the possibilities that homeostatic function of
AMPK may be redundantly performed by other AMPK-related
kinases or that AMPK regulation in tissues other than liver may
be also important. Therefore, future studies should examine
whether AMPK-related kinases are also regulated by the
Sestrins and whether the function of Sestrin2 in other organs,
such as adipose tissue, makes a contribution to the observed
Sesn2/ metabolic phenotypes. Interestingly, ectopic expres-
sion of Sestrin2 and other Sestrin family members induces
AKT phosphorylation, even in cells that are not acutely stimu-
lated with insulin. Sestrin-dependent activation of AKT is also
observed in Drosophila and appears to be mediated via AMPK
and TSC2, whose activity can potentiate activation of mTORC2,
the AKT Ser473 kinase. Clearly, the ability of Sestrins to promoter Inc.
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Figure 7. Sestrin2 Potentiates AKT Signaling through the AMPK-TSC2 Axis
(A) Reduced AKT phosphorylation in Sesn2/ MEFs. Steady state AKT phosphorylation at Thr308 and Ser473 in MEFs grown in the presence of 10% FCS was
examined by immunoblotting.
(B) Reduced insulin-stimulated AKT phosphorylation in Sesn2/ MEFs. After 24 hr of serum starvation, MEFs were collected at the indicated times after insulin
treatment and analyzed for AKT phosphorylation.
(C) Sestrin2 stimulates AKT signaling. Flag-tagged Sestrin2 was induced in MCF7-tet OFF Sesn2F cells by doxycycline (Dox) removal (–). Control cultures were
left with Dox (+). Cell lysates prepared after 24 hr were analyzed for expression and phosphorylation of the indicated proteins.
(D and E) Sestrin2 activation of AKT is TSC2 and AMPK dependent. WT, Tsc2/ or Ampka1//Ampka2/ (Ampknull) MEFs were infected with lentiviral vectors
encoding GFP or Flag-tagged Sestrin2 (Sesn2). Protein phosphorylation and expression were examined at 48 hr after infection by immunoblotting.
(F–K) Activation of AKT by dSestrin in Drosophila wing imaginal discs. Larval wing discs of the indicated strains were stained to visualize AKT phosphorylation
at Ser505 (p-AKT, equivalent to Ser473 in mice). The dorsal side points upward. Dorsoventral boundary (D/V in F) was visualized by staining with an antibody to
the wingless protein (Wg). The indicated transgenic elements were overexpressed only in the dorsal compartment as described (Lee et al., 2010).
See also Figure S7.
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Sestrin2 and Liver Metabolic HomeostasisAMPK activation, suppressmTORC1-S6K signaling and activate
AKT is not cell type specific and therefore takes place in many
different tissues.
It should be noted that unlike Sesn2-/- mice, mice with hepato-
cyte-specific TSC1 ablation do not experience aggravated
hepatosteatosis during obesity (Yecies et al., 2011). This is
probably due to the different mechanisms of action of TSC1
and Sestrin2; unlike TSC1, Sestrin2 activates AMPK, which
can control lipid metabolism in mTORC1-independent ways
(Kahn et al., 2005). For example, AMPK phosphorylates and
inactivates ACC, reducing fatty acid synthesis and indirectlyCell Mestimulating mitochondrial import and oxidation of fatty acids.
AMPK also phosphorylates and activates ULK1/ATG1, which
initiates autophagy (Egan et al., 2011). In addition, AMPK can
promote mitochondrial biogenesis, which can increase b-oxida-
tion (Canto´ et al., 2009). These metabolic outputs of AMPK are
decreased upon Sestrin2 deficiency, and as a result Sesn2/
livers exhibit diminished b-oxidation and aggravated hepatos-
teatosis during obesity. In addition, Sestrin2 deficiency resulted
in the absence of LD-associated autophagosomes, which are
presumably the major pathway for LD digestion and utilization
in hepatocytes (Singh et al., 2009). Another contributor couldtabolism 16, 311–321, September 5, 2012 ª2012 Elsevier Inc. 319
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Sestrin2 loss, although lipogenic gene expression and de novo
lipogenesis in the Sesn2/ liver were not significantly increased.
Regardless of the relative contribution of these molecular
conduits to hepatosteatosis in Sesn2/ mice, it is unlikely that
hepatosteatosis per se is responsible for the metabolic defects
in these mice, as certain strains of mice can exhibit fatty liver
without marked metabolic abnormalities (Farese et al., 2012).
Further supporting this idea, Sesn2//Sesn3/ mice exhibit
hepatic insulin resistance without displaying any signs of aber-
rant fat accumulation in liver.
Our results indicate that Sestrin2 is the only Sestrin protein that
is inducible upon hypernutrition and obesity in mouse liver.
Therefore, although Sesn2/mice continue to express Sestrin1
and Sestrin3, they are clearly more insulin resistant and glucose
intolerant than control mice when rendered obese. As a result,
Sesn2//Lepob/ob mice become extremely diabetic, while
Sesn2+//Lepob/obmice display relatively mild insulin resistance.
In addition, obese Sesn2/mice accumulate more lipids in their
livers than Con mice. These pronounced phenotypes, however,
are unlikely due to unique biochemical functions of Sestrin2
that are not shared with Sestrin1 and Sestrin3. Cell culture
studies indicate that all three mammalian Sestrins and dSestrin
can potentiate AMPK activation, and the defects exhibited by
Sesn2/ mice are consistent with reduced AMPK activity and
subsequent increase in mTORC1 activation. Indeed, combined
Sestrin2 and Sestrin3 deficiency causes insulin resistance in
nonobese mice and alters mTORC1-S6K signaling in both liver
and muscle. It is also worth mentioning that ATM/p53 signaling
mutations in humans and mice, which strongly reduce hepatic
expression of Sestrin1–Sestrin3, are associated with insulin
resistance and aberrant glucose metabolism (Armata et al.,
2010; Bar et al., 1978; Schneider et al., 2006). Given their induc-
tion by genotoxic stress and their ability to control glucose and
lipid homeostasis, the Sestrins may represent the missing link
between DNA damage and metabolism.
EXPERIMENTAL PROCEDURES
Mice and Diets
Sesn2/ mice (Budanov and Karin, 2008) were backcrossed to the C57BL/6
strain for at least seven generations. Sesn3/ mice on the C57BL/6 back-
ground were generated from ESCs obtained from EUCOMM. These cells
were created by targeted gene trap approach and contain reporter-tagged
insertion within intron 5 of the Sesn3 gene with a strong splice acceptor site
expressing a b-gal-Neo fusion protein that disrupts the Sesn3 ORF. Lepob
mice also in the C57BL/6 background were purchased from the Jackson
Lab. Mice were maintained in filter-topped cages and were given free access
to autoclaved regular chow diet (LFD) or HFD (composed of 59% fat, 15%
protein, 26% carbohydrates based on caloric content; Bio-Serv) and water
at University of California, San Diego (UCSD) or University of Michigan (UM)
according to National Institutes of Health (NIH) and institutional guidelines.
All animal studies were overseen by the University Committee on Use and
Care of Animals (UCUCA) at UM or by the Institutional Animal Care and Use
Committee (IACUC) at UCSD.
Mammalian Cell Culture and Biochemical Assays
MCF7-tet OFF Sesn2F cells were described (Budanov and Karin, 2008).
Immortalized Sesn2+/+ and Sesn2/ fibroblasts were generated by infection
of MEFs with a lentiviral vector expressing ARF1 shRNA. Immortalized
Ampka1//Ampka2/ fibroblasts were described (Laderoute et al., 2006),
and Tsc2+/+ and Tsc2/ immortalized fibroblasts were obtained from320 Cell Metabolism 16, 311–321, September 5, 2012 ª2012 ElsevieD. Kwiatkowsky. Cell culture conditions, MCF7-tet OFF system, and infection
with retroviral vectors were described (Budanov and Karin, 2008). Immuno-
blotting, RNA analysis, immune complex kinase assay, lipid metabolism
assays, and adenoviral procedures are described in the Supplemental Exper-
imental Procedures.
Evaluation of Glucose Homeostasis
For glucose and insulin tolerance tests, mice were starved for 6 or 12 hr as
indicated. Blood was drawn from a tail nick at the indicated time points after
i.p. injection of glucose (1 g/kg body weight) or insulin (0.65 U/kg body weight),
and blood glucose was instantly measured with a one-touch ultra glucose
meter. Hyperinsulinemic-euglycemic clamps were performed with an infusion
of 12 mU insulin/kg body weight per minute as described (Oh et al., 2010).
Glucose uptake assay in primary adipocytes and serum insulin measurement
were done as described (Oh et al., 2010). Glucose in urine was quantified as in
the Supplemental Experimental Procedures.
Histology
EM and fluorescence staining were done as described in the Supplemental
Experimental Procedures. Oil red O staining of frozen liver sections (Park
et al., 2010) and immunostaining of Drosophila imaginal discs (Lee et al.,
2010) were described.
Statistical Analysis
Data are presented as means ± standard error or means ± standard deviation
as indicated in legends. p values were calculated with a Student’s t test or
two-way ANOVA as indicated.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2012.08.004.
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